Stocks and Investing
Stocks and Investing
Fri, June 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, June 23, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Kalpit Patel Initiated (VRDN) at Strong Buy and Held Target at $25 on, Jun 23rd, 2022
Kalpit Patel of B. Riley Securities, Initiated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $25 on, Jun 23rd, 2022.
Kalpit has made no other calls on VRDN in the last 4 months.
There is 1 other peer that has a rating on VRDN. Out of the 1 peers that are also analyzing VRDN, 0 agree with Kalpit's Rating of Hold.
This is the rating of the analyst that currently disagrees with Kalpit
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $31 on, Friday, March 11th, 2022
Contributing Sources